Table 2 Convergent Functional Evidence (CFE) for best predictive biomarkers for stress (from Fig. 2)
From: Towards precision medicine for stress disorders: diagnostic biomarkers and targeted drugs
Gene symbol/gene name | Probesets | Step 1 | Step 2 | Step 3 | Step 4 | Step 4 | Step 4 | Step 5 | Step 6 | CFE Polyevidence Score |
|---|---|---|---|---|---|---|---|---|---|---|
Discovery in blood | External CFG evidence for involvement in stress | Validation in blood | Best significant prediction of high stress state | Best significant prediction of first-year Hosp with stress | Best Significant predictions of all future Hosp with stress | Other psychiatric and related disorders evidence—change in same direction as stress | Pharmacogenomics drugs that modulate the biomarker in opposite direction to stress | |||
(Direction of change) method/score/% | Score | ANOVA p value/score | ROC AUC/p value | ROC AUC/p value | OR/OR p value | |||||
6 pts | 12 pts | 6 pts | 8 pts All; 6 pts Gender; 4 pts Gender/Dx | 8 pts All; 6 pts Gender; 4 pts Gender/Dx | 8 pts All; 6 pts Gender; 4 pts Gender/Dx | 3 pts | 3 pts | |||
TL Telomere Length Reference marker from literature | NA | NA | 7 | NS | Gender/Dx M-MDD C: (2/14) 1/1.42E-02 | All C: (14/108) 0.72/4.82E-03 Gender Male C: (14/86) 0.73/3.21E-03 Gender/Dx M-MDD C: (4/17) 0.90/8.71E-03 M-BP C: (9/55 0.68/4.19E-02 | Aging Alcohol Depression Mania Psychosis | Omega-3 fatty acids Lithium Olanzapine Mianserin | 25 | |
FKBP5 FK506 Binding Protein 5 | 224856_at | (D) DE/4 53.8% | 12 | 1.22E-02/4 Nominal | Gender Female C: (13/60) 0.65/4.85E-02 Gender/Dx F-BP C: (6/22) 0.82/1.11E-02 | Gender/Dx M-MDD C: (5/49) 0.75/3.72E-02 L: (2/27) 0.9/3.20E-02 | Gender/Dx M-SZ L: (8/56) 4.6/3.94E-02 | Alcohol Anxiety BP Depression MDD Pain Psychosis Unipolar Depression Suicide | Mood stabilizers | 40 |
DDX6 DEAD-Box Helicase 6 | 1562836_at | (I) DE/6 83.8% (I) AP/6 90.2% | 9 | Not stepwise | All L: (13/134) 0.64/4.79E-02 Gender Female C: (13/60) 0.7/1.60E-02 L: (5/33) 0.79/2.23E-02 Gender/Dx F-BP C: (6/22) 0.82/1.11E-02 L: (2/12) 0.9/4.28E-02 M-PSYCHOSIS C: (5/47) 0.73/4.88E-02 L: (2/24) 0.95/1.84E-02 M-SZ C: (4/29) 0.87/9.64E-03 L: (2/15) 1/1.36E-02 | All L: (14/234) 0.63/4.59E-02 Gender Male L: (14/206) 0.64/4.00E-02 Gender/Dx M-BP L: (10/77) 0.71/1.63E-02 | All L: (62/286) 1.3/4.41E-02 Gender Male L: (59/253) 1.4/1.66E-02 Gender/Dx M-BP L: (24/91) 1.8/2.75E-05 | Alcohol BP Other substances/addictions MDD Yohimbine Suicide | 36 | |
B2M Beta-2-Microglobulin | 232311_at | (I) DE/6 91.2% | 5 | Not stepwise | Gender/Dx F-PSYCHOSIS C: (4/19) 0.93/4.66E-03 F-SZA C: (3/13) 0.9/2.13E-02 | Gender Female C: (2/46) 0.94/1.78E-02 | All C: (113/474) 1.2/3.09E-02 L: (62/286) 1.5/9.79E-03 Gender Female C: (7/53) 1.8/4.87E-02 Male L: (59/253) 1.5/6.83E-03 Gender/Dx M-BP C: (41/140) 1.4/2.02E-03 L: (24/91) 2.3/5.64E-04 | Alcohol Aging Autism Eating disorder MDD Depression Pain Suicide | Omega-3 fatty acids, 4’-iodo-4’-deoxydoxorubicin | 35 |
LAIR1 Leukocyte Associated Immunoglobulin Like Receptor 1 | 210644_s_at | (D) DE/6 86.2% | 4 | 1.12E-02/4 Nominal | Gender Female L: (5/33) 0.75/3.94E-02 | Gender/Dx M-PSYCHOSIS L: (2/95) 0.85/4.35E-02 | All L: (62/286) 1.7/1.68E-03 Gender Male L: (59/253) 1.7/2.09E-03 Gender/Dx M-BP L: (24/91) 2/1.76E-02 M-PSYCHOSIS L: (29/121) 1.7/1.22E-02 | Suicide | 35 | |
RTN4 Reticulon 4 | 1556049_at | (I) DE/4 54.4% | 9 | Not stepwise | All C: (32/398) 0.63/9.49E-03 Gender Female C: (2/46) 0.85/4.75-02 Male C: (30/352) 0.61/2.32-02 | All C: (113/474) 1.18/2.26-02 Gender Male C: (106/421) 1.16/4.30-02 Gender/Dx M-BP C: (41/140) 1.29/4.95-02 M-MDD C: (9/57) 2.21/1.33-02 F-SZA C: (3/12) 5.4/4.76-02 | Alcohol BP Suicide Pain | Omega-3 fatty acids Valproate | 35 | |
NUB1 Negative Regulator Of Ubiquitin Like Proteins 1 | 1560108_at (1560109_s_at) | (I) DE/4 61.8% | 8 | 2.34E-02/4 Nominal (6.22E-04/4 Top Nominal) | All C: (38/258) 0.65/1.42E-03 Gender Female C: (13/60) 0.74/3.96E-03 Male C: (25/198) 0.6/4.70E-02 Gender/Dx F-BP C: (6/22) 0.78/2.33E-02 | Gender/Dx M-PSYCHOSIS C: (52/201) 1.2/2.72E-02 L: (29/121) 1.5/1.37E-02 M-SZ L: (8/56) 1.6/2.20E-02 | Autism Suicide | Antipsychotics | 34 | |
CIRBP Cold Inducible RNA Binding Protein | 200811_at | (D) DE/4 69.2% | 4 | 3.66E-02/4 Nominal | Gender Female C: (13/60) 0.65/4.67E-02 Gender/Dx F-BP C: (6/22) 0.76/3.27E-02 L: (2/12) 1/1.58E-02 | All L: (14/234) 0.68/1.19E-02 Gender Male L: (14/206) 0.68/1.17E-02 Gender/Dx M-BP L: (10/77) 0.67/4.63E-02 M-SZ C: (3/74) 0.79/4.59E-02 | Gender/Dx M-BP L: (24/91) 1.9/1.99E-02 M-MDD L: (4/32) 13/3.39E-02 M-SZ L: (8/56) 4.1/1.23E-02 | Autism SZ | 33 | |
CYP2E1 Cytochrome P450 Family 2 Subfamily E Member 1 | 209976_s_at | (I) DE/2 44.1% | 6 | 1.57E-02/4 Nominal | Gender/Dx F-BP C: (6/22) 0.78/2.33E-02 M-MDD C: (6/35) 0.77/1.98E-02 | All C: (32/398) 0.6/3.41E-02 Gender Male C: (30/352) 0.63/1.09E-02 Gender/Dx M-PSYCHOSIS C: (8/161) 0.74/1.04E-02 M-SZA C: (5/87) 0.82/7.64E-03 | Gender Male L: (59/253) 1.3/4.96E-02 Gender/Dx M-PSYCHOSIS L: (29/121) 1.6/9.44E-03 M-SZ C: (13/93) 1.4/3.85E-02 L: (8/56) 2.1/2.50E-03 | Alcohol SZ Suicide | 33 | |
MAD1L1 MAD1 Mitotic Arrest Deficient Like 1 | 204857_at | (D) DE/4 72.3% | 2 | 1.47E-02/4 Nominal | Gender/Dx F-PSYCHOSIS C: (4/19) 0.78/4.45E-02 | All L: (14/236) 0.64/4.24E-02 Gender Male L: (14/208) 0.64/4.07E-02 | All L: (62/288) 1.8/1.32E-03 Gender Male L: (59/255) 1.7/2.66E-03 Gender/Dx M-BP L: (24/91) 2.1/9.71E-03 M-MDD L: (4/32) 31.4/5.50E-03 | Autism BP Cocaine SZ | 33 | |
OAS1 2’-5’-Oligoadenylate Synthetase 1 | 202869_at | (D) DE/4 56.9% | 9 | 1.15E-01/2 Stepwise | All C: (38/258) 0.6/2.77E-02 Gender Female C: (13/60) 0.66/3.71E-02 Gender/Dx F-PSYCHOSIS C: (4/19) 0.8/3.59E-02 | Gender/Dx M-PSYCHOSIS L: (29/121) 2.7/1.52E-02 M-SZ L: (8/56) 3.5/4.35E-02 | Alcohol Alzheimer’s Panic disorder MDD | Mood stabilizers | 33 | |
OXA1L OXA1L, Mitochondrial Inner Membrane Protein | 208717_at | (D) DE/4 56.9% | 6 | 6.40E-03/4 Nominal | Gender/Dx F-BP C: (6/22) 0.75/3.84E-02 | Gender/Dx M-MDD L: (2/27) 0.86/4.78E-02 | All L: (62/288) 1.5/1.14E-02 Gender Male L: (59/255) 1.5/2.04E-02 Gender/Dx F-PSYCHOSIS C: (6/17) 4.2/3.02E-02 M-MDD L: (4/32) 3.5/4.37E-02 M-SZ L: (8/56) 4.7/2.19E-02 | Autism BP Suicide SZ | 33 | |
CCL4 C-C Motif Chemokine Ligand 4 | 204103_at | (D) DE/6 96.9% | 2 | Not stepwise | Gender/Dx F-PTSD C: (3/7) 1/1.69E-02 M-MDD C: (6/35) 0.75/2.99E-02 | All L: (14/234) 0.66/2.01E-02 Gender Male L: (14/206) 0.66/2.07E-02 Gender/Dx M-MDD L: (2/27) 0.94/2.08E-02 | All L: (62/286) 1.4/3.22E-02 Gender Male L: (59/253) 1.6/1.01E-02 Gender/Dx M-BP L: (24/91) 2.2/5.34E-03 M-MDD L: (4/32) 54.5/2.12E-02 | Alcohol Depression MDD SZ | 31 | |
DTNBP1 Dystrobrevin Binding Protein 1 | 223446_s_at | (D) DE/6 93.8% | 4 | Not stepwise | Gender Female C: (13/60) 0.7/1.33E-02 Gender/Dx F-PSYCHOSIS C: (4/19) 0.9/8.20E-03 F-SZA C: (3/13) 0.93/1.40E-02 | Gender/Dx M-MDD C: (9/57) 3.1/2.45E-02 | All L: (62/286) 1.4/2.26E-02 Gender Male L: (59/253) 1.5/7.76E-03 Gender/Dx M-BP L: (24/91) 1.9/2.78E-03 M-SZA C: (39/108) 1.5/1.55E-02 | Autism Intellect Methamphetamine Psychosis SZ BP MDD Suicide | 31 | |
SPON2 Spondin 2 | 218638_s_at | (D) DE/6 93.8% | 2 | Not stepwise | Gender/Dx F-PTSD C: (3/7) 1/1.69E-02 | All L: (14/234) 0.66/2.24E-02 Gender Male L: (14/206) 0.66/2.19E-02 Gender/Dx M-BP L: (10/77) 0.67/4.20E-02 M-MDD C: (5/49) 0.83/8.70E-03 L: (2/27) 0.88/3.93E-02 | All L: (62/286) 1.6/8.58E-03 Gender Male L: (59/253) 1.7/4.62E-03 Gender/Dx M-BP L: (24/91) 4.4/9.90E-04 M-MDD L: (4/32) 14.6/1.88E-02 | Autism BP Panic disorder SZ | 31 | |
ANK2 Ankyrin 2 | 202921_s_at | (I) DE/4 52.9% | 2 | 1.09E-02/4 Nominal | Gender Female C: (13/60) 0.66/4.33E-02 F-BP C: (6/22) 0.75/3.84E-02 M-MDD C: (6/35) 0.72/4.81E-02 | Gender/Dx M-MDD C: (5/49) 0.75/3.22E-02 L: (2/27) 0.96/1.66E-02 | Gender/Dx M-MDD L: (4/32) 76.8/8.14E-03 | Autism Alcohol BP Longevity ASD Chronic fatigue syndrome MDD Suicide SZ | Antidepressants | 30 |
LAIR2 Leukocyte Associated Immunoglobulin Like Receptor 2 | 207509_s_at | (D) DE/6 98.5% | 0 | Not stepwise | Most reproducibly predictive for state All C: (38/258) 0.62/1.15E-02 Gender Female C: (13/60) 0.81/3.37E-04 L: (5/33) 0.81/1.36E-02 Gender/Dx F-BP C: (6/22) 0.86/4.94E-03 L: (2/12) 1/1.58E-02 F-PTSD C: (3/7) 1/1.69E-02 M-MDD C: (6/35) 0.76/2.44E-02 | Gender Female C: (2/46) 0.97/1.36E-02 | Gender/Dx M-BP L: (24/91) 2.6/7.13E-03 M-MDD L: (4/32) 5.5/4.21E-02 | Suicide | Antidepressants | 30 |
SUMO1 Small Ubiquitin-Like Modifier 1 | 208762_at | (D) DE/4 56.3% | 9 | Not stepwise | Gender Female C: (13/60) 0.70/1.46E-02 Gender/Dx F-BP C: (6/22) 0.75/3.84-02 L: (2/12) 0.9/4.28-02 | Gender/Dx M-SZ C: (3/74) 0.87/1.57-02 L: (1/44) 1/4.52-02 | Gender/Dx M-SZ C: (13/93) 2.98/2.98-02 L: (8/56) 3.26/3.07-02 | Aging BP SZ | 30 | |
MKL2 MKL1/Myocardin Like 2 | 1562497_at | (I) AP/4 60.8% | 2 | 4.58E-02/4 Nominal | Most reproducibly predictive for trait first year All C: (32/398) 0.59/3.79E-02 Gender Male C: (30/352) 0.61/2.53E-02 L: (14/206) 0.64/4.33E-02 Gender/Dx M-BP L: (10/77) 0.67/3.81E-02 M-MDD L: (2/27) 0.88/3.93E-02 M-PSYCHOSIS C: (8/161) 0.68/3.94E-02 | All C: (113/474) 1.2/7.86E-03 L: (62/286) 1.4/3.45E-03 Gender Male C: (106/421) 1.2/1.84E-02 L: (59/253) 1.3/7.90E-03 Gender/Dx M-BP C: (41/140) 1.3/3.59E-03 L: (24/91) 1.6/6.70E-04 M-MDD L: (4/32) 3.3/1.73E-02 | Autism SZ | 29 | ||
DMGDH Dimethylglycine Dehydrogenase | 231591_at | (I) DE/2 45.6% | 4 | 3.36E-02/4 Nominal | Gender/Dx F-BP C: (6/22) 0.77/2.76E-02 | Gender/Dx M-SZ L: (1/44) 1.0/4.52E-02 | Gender Male L: (59/255) 1.3/4.80E-02 Gender/Dx M-BP L: (24/91) 1.6/2.89E-02 M-PSYCHOSIS C: (52/201) 1.3/1.69E-02 M-SZ C: (13/93) 1.4/2.67E-02 L: (8/56) 2.8/1.52E-02 | Delusion Suicide | 27 | |
N4BP2L2 NEDD4 Binding Protein 2 Like 2 | 214388_at | (I) DE/4 69.1% | 4 | 4.40E-02/4 Nominal | Gender/Dx F-BP C: (6/22) 0.77/2.76E-02 L: (2/12) 0.95/2.66E-02 | Gender/Dx M-BP L: (10/77) 0.74/7.66E-03 M-SZ C: (3/74) 0.82/3.02E-02 | Gender/Dx M-BP L: (24/91) 1.5/1.13E-02 | BP MDD SZ Suicide | 27 | |
PCDHB6 Protocadherin Beta 6 | 239443_at | (I) DE/2 38.2% | 6 | 1.17E-02/4 Nominal | All C: (38/258) 0.61/1.31E-02 Gender Male C: (25/198) 0.65/7.19E-03 Gender/Dx M-BP C: (10/101) 0.67/4.20E-02 | Gender/Dx M-PSYCHOSIS L: (29/121) 1.5/1.51E-02 M-SZ L: (8/56) 1.8/1.98E-02 | Suicide | 27 | ||
SNCA Synuclein Alpha | 215811_at | (D) AP/2 37.5% | 11 | Not stepwise | Gender/Dx M-PSYCHOSIS L: (2/24) 0.98/1.41E-02 M-SZ L: (2/15) 1/1.36E-02 | Gender/Dx M-SZA C: (39/108) 1.6/3.62E-02 | Alcohol Aggression Alzheimer’s BP MDD Methamphetamine Parkinson Suicide SZ | Omega-3 fatty acids Mood stabilizers | 27 | |
GJB2 Gap Junction Protein Beta 2 | 223278_at | (I) DE/2 48.5% | 6 | 2.42E-02/4 Nominal | Gender/Dx M-MDD C: (6/35) 0.82/7.12E-03 | Gender/Dx M-SZ L: (8/56) 2.2/2.37E-02 | MDD | Antipsychotics | 26 | |
HIF1A Hypoxia Inducible Factor 1 Alpha Subunit | 238869_at | (I) DE/4 54.4% | 4 | 1.11E-02/4 Nominal | Most reproducibly predictive for trait all future All C: (113/474) 1.2/3.86E-02 L: (62/288) 1.5/1.28E-02 Gender Male C: (106/421) 1.2/1.42E-02 L: (59/255) 1.5/5.53E-03 Gender/Dx M-BP L: (24/91) 1.5/3.84E-02 M-PSYCHOSIS C: (52/201) 1.3/1.91E-02 L: (29/121) 1.7/2.57E-02 M-SZ C: (13/93) 1.7/3.44E-02 L: (8/56) 3.3/1.75E-02 | Alcohol Autism BP MDD Longevity Pain SZ | EZN 2968 | 26 | ||
PSD3 Pleckstrin And Sec7 Domain Containing 3 | 218613_at | (D) AP/6 100% | 2 | Not stepwise | Gender Female C: (2/46) 0.98/1.18E-02 | Gender Female C: (7/53) 2.2/4.42E-02 | Autism Alcohol ASD BP SZ MDD Methamphetamine Chronic fatigue syndrome Suicide | Antipsychotics | 26 | |
STX11 Syntaxin 11 | 210190_at | (D) DE/2 49.2% | 4.5 | 2.74E-02/4 Nominal | Gender/Dx M-MDD C: (6/35) 0.74/3.64E-02 | Gender/Dx M-MDD C: (5/49) 0.95/4.78 -04 | Gender/Dx M-MDD C: (9/57) 3.1/2.45E-02 | Antidepressants Mood stabilizers | 25.5 | |
APOL3 Apolipoprotein L3 | 221087_s_at | (D) AP/4 50% | 2 | 2.96E-02/4 Nominal | All L: (14/234) 0.7/5.34E-03 Gender Male L: (14/206) 0.71/4.53E-03 Gender/Dx M-MDD L: (2/27) 0.92/2.59E-02 | Gender/Dx F-SZA C: (3/12) 8.1/4.33E-02 M-MDD L: (4/32) 9.6/2.59E-02 | ADHD Suicide SZ | 25 | ||
ELMO2 Engulfment And Cell Motility 2 | 220363_s_at | (D) DE/4 60.0% (D) AP/4 54.7% | 2 | 1.30E-02/4 Nominal | Gender/Dx M-MDD C: (5/49) 0.78/2.20E-02 L: (2/27) 0.92/2.59E-02 | All L: (62/288) 1.44/3.31E-02 Gender Male L: (59/255) 1.39/4.91E-02 Gender/Dx M-MDD C: (9/57) 3.86/8.54E-03 L: (4/32) 6.07/3.64E-02 F-PSYCHOSIS L: (6/17) 2.36/4.48E-02 | Suicide | 25 | ||
UBE2E2 Ubiquitin Conjugating Enzyme E2 E2 | 225651_at | (D) DE/4 53.8% | 4 | 4.41E-02/4 Nominal | Gender Female C: (13/60) 0.68/2.58E-02 F-BP C: (6/22) 0.76/3.27E-02 | Gender/Dx M-PSYCHOSIS C: (52/201) 1.4/5.21E-03 M-SZA C: (39/108) 1.6/2.83E-03 | Psychosis | 25 | ||
FKBP5 FK506 Binding Protein 5 | 224840_at | (D) DE/2 41.5% | 12 | Not stepwise | Gender/Dx M-SZ L: (8/56) 3.4/3.84E-02 | Alcohol Anxiety BP Depression MDD Pain Psychosis Unipolar Depression Suicide | Mood stabilizers Psychotherapy | 24 | ||
HLA-DRB1 Major Histocompatibility Complex, Class II, DR Beta 1 | 209312_x_at | (D) DE/2 41.5% | 4 | 1.22E-02/4 Nominal | All L: (62/286) 1.7/5.17E-03 Gender Male L: (59/253) 1.6/1.21E-02 Gender/Dx F-PSYCHOSIS C: (6/17) 3.1/2.62E-02 F-SZA C: (3/12) 39.3/4.08E-02 M-SZA C: (39/108) 1.4/2.18E-02 L: (21/65) 1.7/4.72E-02 | Alcohol BP Longevity Alzheimer’s disease SZ Pain Panic Disorder | Apolizumab | 24 | ||
LCP2 Lymphocyte Cytosolic Protein 2 | 244251_at | (D) DE/4 53.8% | 3 | 2.01E-02/4 Nominal | Gender Male C: (30/352) 0.61/2.19E-02 Gender/Dx M-SZA C: (5/87) 0.85/4.09E-03 M-PSYCHOSIS C: (8/161) 0.78/3.90E-03 | Gender/Dx M-SZ C: (13/93) 1.46/4.14E-02 L: (8/56) 2.17/2.38E-02 | MDD | 24 | ||
LRRC59 Leucine Rich Repeat Containing 59 | 222231_s_at | (D) DE/4 61.5% | 2 | 3.15E-02/4 Nominal | All L: (62/286) 1.35/4.50E-02 Gender Male L: (59/253) 1.38/3.67E-02 Gender/Dx F-SZA C: (3/12) 56.1/4.25E-02 | SZ | Valproate | 24 | ||
FOXK2 Forkhead Box K2 | 220696_at | (I) DE/4 58.8% (I) AP/4 72.5% | 2 | 1.52E-02/4 Nominal | Gender Female C: (13/60) 0.68/2.18E-02 L: (5/33) 0.88/3.89E-03 Gender/Dx F-BP C: (6/22) 0.76/3.27E-02 L: (2/12) 1/1.58E-02 F-PTSD C: (3/7) 1/1.69E-02 | Gender/Dx M-SZ L: (8/56) 2.2/1.09E-02 | Alcohol Autism Delusions Hallucinations Suicide | 23 | ||
HLA-B Major Histocompatibility Complex, Class I, B | 211911_x_at | (D) DE/4 52.3% | 3 | 4.85E-02/4 Nominal | Gender/Dx M-MDD C: (5/49) 0.85/4.99E-03 L: (2/27) 1.0/1.03E-02 | All L: (62/288) 1.65/4.74E-03 Gender Male L: (59/255) 1.66/4.25E-03 Gender/Dx M-MDD L: (4/32) 5.35/1.09E-02 M-BP L: (24/91) 1.76/1.10E-02 | 23 | |||
NKTR Natural Killer Cell Triggering Receptor | 243055_at | (I) DE/4 50% (I) AP/2 43.1% | 4 | 1.24E-02/4 Nominal | All C: (113/474) 1.4/9.52E-05** Gender Male C: (106/421) 1.4/1.43E-04** Gender/Dx M-BP C: (41/140) 1.6/5.56E-05** M-PSYCHOSIS C: (52/201) 1.3/1.06E-02 M-SZ C: (13/93) 1.7/5.58E-03 L: (8/56) 1.7/4.98E-02 | Alcohol BP MDD Suicide SZ | 23 | |||
PLEKHA5 Pleckstrin Homology Domain Containing A5 | 239559_at | (I) DE/2 35.3% | 4 | 3.33E-02/4 Nominal | Gender/Dx M-SZ C: (3/74) 0.91/8.24E-03 | Gender Male C: (106/421) 1.2/4.50E-02 Gender/Dx M-BP L: (24/91) 1.6/1.15E-02 | BP Suicide | 23 | ||
C1orf123 Chromosome 1 Open Reading Frame 123 | 203197_s_at | (D) DE/4 72.3% | 2 | 2.92E-02/4 Nominal | All L: (62/288) 1.5/1.44E-02 Gender Female L: (3/33) 12.3/3.35E-02 Gender Male L: (59/255) 1.3/4.43E-02 F-PSYCHOSIS C: (6/17) 3.5/2.00E-02 M-MDD L: (4/32) 3/3.73E-02 | Suicide | 21 | |||
UQCC1 Ubiquinol-Cytochrome C Reductase Complex Assembly Factor 1 | 217935_s_at | (D) DE/2 38.5% | 4 | 3.33E-02/4 Nominal | Gender/Dx M-BP C: (10/101) 0.72/1.18E-02 | Gender/Dx M-SZ C: (3/74) 0.89/1.19E-02 | BP Suicide | 21 | ||
PCBP2 Poly(RC) Binding Protein 2 | 237374_at | (I) DE/2 35.3% | 4.5 | 2.83E-02/4 Nominal | Gender/Dx F-BP C: (6/22) 0.89/3.19-03 L: (2/12) 1/1.58-02 M-SZ C: (4/29) 0.8/2.89-02 | BP Suicide | 17.5 | |||
DCTN5 Dynactin Subunit 5 | 209231_s_at | (D) DE/6 90.8% | 2 | Not stepwise | Gender/Dx F-PSYCHOSIS C: (6/17) 3.3/3.22E-02 M-SZ L: (8/56) 6.5/4.80E-03 | BP Suicide | 15 | |||
LOC105378349 Uncharacterized LOC105378349 | 241143_at | (D) AP/6 90.6% | 0 | Not stepwise | Gender/Dx M-PSYCHOSIS C: (5/47) 0.74/4.22E-02 | Gender/Dx M-BP C: (41/140) 1.4/2.00E-02 M-MDD C: (9/57) 2.4/2.68E-02 | 14 |
